New Drug Shows Promise in Killing Mesothelioma Tumor CellsResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2022, December 19). New Drug Shows Promise in Killing Mesothelioma Tumor Cells. Asbestos.com. Retrieved January 27, 2023, from https://www.asbestos.com/news/2013/12/19/mesothelioma-chemotherapy-clinical-trial/
Povtak, Tim. "New Drug Shows Promise in Killing Mesothelioma Tumor Cells." Asbestos.com, 19 Dec 2022, https://www.asbestos.com/news/2013/12/19/mesothelioma-chemotherapy-clinical-trial/.
Povtak, Tim. "New Drug Shows Promise in Killing Mesothelioma Tumor Cells." Asbestos.com. Last modified December 19, 2022. https://www.asbestos.com/news/2013/12/19/mesothelioma-chemotherapy-clinical-trial/.
There may be help on the horizon for future pleural mesothelioma patients needing an effective, first-line systemic chemotherapy regimen that doesn’t exist
The latest laboratory breakthrough could give them a much better chance at survival.
A recently completed study of panobinostat, a new experimental drug, in combination with the standard cisplatin, showed promising results in killing mesothelioma tumor cells
without harming the healthy ones, along with eliminating the often troubling side effects.
The study, published in Genetics and Molecular Research, was conducted in
Ankara, Turkey, at Gazi University.
“None of the currently used standard treatments are acceptable for MPM ( malignant pleural mesothelioma). Studies are needed,” professor H. Ilke Onen, Ph.D.,
Department of Medical Biology & Genetics, Gazi University, told Asbestos.com. “But we found promising results for killing [mesothelioma] tumor cells.”
Still in Early Stages
Onen was quick to point out that his findings in the laboratory were just the start of what would be lengthy process in bringing a potential therapy to
market, but the initial research was eye-opening and eventually could move the medical community closer to a more effective treatment.
Pleural mesothelioma today is typically treated with a FDA-approved chemotherapy combination of cisplatin and pemetrexed, although the response has been
far from effective. The majority of mesothelioma patients undergoing treatment do not live beyond 18 months after diagnosis.
Panobinostat, which is being developed by pharmaceutical giant Novartis, has the ability to stop production of enzymes that allow mesothelioma cancer cells
to grow at the molecular level. When the expression of those enzymes is inhibited, the cancer cells are unable to spread. It has shown considerable promise
when combined with cisplatin.
“It’s too early to predict an outcome of treatment with that combination [of panobinostat and cisplatin],” Onen said. But they found “an effective cell
death response by making cells more susceptible to [cisplatin].”
Panobinostat Tested with Other Cancers
Panobinostat and cisplatin also are being tested successfully with other cancers, including multiple myeloma and lymphoma.
The combination of the two drugs, according to test results, was considerably more effective than using each drug separately. Mesothelioma cells were
unable to survive in the laboratory while the healthy cells continued to thrive.
The combination of the two drugs also did not show the same inhibited gene expression, which the authors believe would eliminate the toxic side effects
that also comes with typical systemic chemotherapy. It would allow for a much stronger dose.
“The result is a more effective removal of tumor cells,” the authors wrote in the article.
Despite the impressive study results, Onen said the laboratory results were only the first step. His research group already has moved into the second step
that would include animal models. If that phase is successful, then another clinical trial will begin using actual mesothelioma patients.
“Only if the safety of the anti-cancer agents is confirmed by these three critical steps, then patients can be treated with this new anti-cancer agent,”